Ryvu Therapeutics Presents Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting
December 11, 2023 01:45 ET
|
Ryvu Therapeutics
Clinical activity observed in 50% of evaluable patients with relapsed/refractory acute myeloid leukemia (r/r AML) or high-risk myelodysplastic syndromes (HR-MDS) treated with RVU120 monotherapy,...
Ryvu Therapeutics Presents Data on RVU120 at the San Antonio Breast Cancer Symposium 2023
December 07, 2023 08:30 ET
|
Ryvu Therapeutics
Translational data demonstrate synergistic activity of RVU120 and MEK inhibitors in hormone receptor-negative breast cancer KRAKOW, Poland, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics...
Ryvu Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 29, 2023 11:30 ET
|
Ryvu Therapeutics
The total operating revenues amounted to $11.9M and increased by 42% compared to Q3 2022.Updated data from Phase Ib study of RVU120 in AML/HR-MDS to be presented at the upcoming American Society of...
Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Solid Tumors and AML/HR-MDS, and Presents the Updated Development Plan for RVU120
October 23, 2023 02:50 ET
|
Ryvu Therapeutics
KRAKOW, Poland, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...
Ryvu Therapeutics to Present Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 04, 2023 12:30 ET
|
Ryvu Therapeutics
Poster presentations highlight preclinical data from Ryvu’s PRMT5 program in MTAP-Deficient cancers and its synthetic lethality platform in colorectal cancer modelsVirtual webinar on PRMT5 data and...
Ryvu Therapeutics Reports 2023 Half-Year Financial Results and Provides Corporate Update
September 13, 2023 03:00 ET
|
Ryvu Therapeutics
The total operating revenues amounted to $7.9M and increased by 131% compared to H1 2022.Updated clinical and preclinical data on RVU120 were presented at the European Hematology Associated (EHA)...
Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2023 European Hematology Association Congress
June 09, 2023 03:15 ET
|
Ryvu Therapeutics
Ongoing Phase 1b Dose-Escalation Study of Single-Agent Treatment with RVU120 in Patients with AML or High-Risk MDS Shows Clinical Benefit and Favorable Safety;Dose-Escalation Continues, Currently...
Ryvu Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 16, 2023 11:58 ET
|
Ryvu Therapeutics
Updated Clinical Data from the Ongoing Phase Ib Dose-Escalation Study of RVU120 in Patients with AML or High-Risk MDS and Preclinical Data from the Combination Study of RVU120 and Ruxolitinib in...
Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the 2023 European Hematology Association Congress
May 11, 2023 11:16 ET
|
Ryvu Therapeutics
Updated Clinical Data from the Ongoing Phase 1b Dose-Escalation Study of RVU120 in Patients with AML or High-Risk MDS Show Favorable Safety and Promising Signs of EfficacyPoster Presentation to...
Ryvu Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 24, 2023 03:30 ET
|
Ryvu Therapeutics
Signed a collaboration agreement with BioNTech to develop and commercialize immunomodulatory small molecule therapeutics; deal terms included €20M upfront payment, €20M equity investment in Ryvu,...